Stonepine group discloses sub-10% Edesa Biotech (NASDAQ: EDSA) position

Rhea-AI Filing Summary

Edesa Biotech, Inc. (EDSA) has a new large shareholder group reported on Schedule 13G. Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico jointly report beneficial ownership of 953,739 Edesa common shares, representing 6.9% of the class.

The position consists of 703,739 common shares plus warrants to acquire an additional 250,000 common shares, subject to a 9.99% beneficial ownership limitation. The percentage is based on 13,503,723 common shares outstanding immediately after an offering, as reported in a prospectus dated August 20, 2026. Voting and dispositive power over the 953,739 shares is shared among the Stonepine entities and Plexico, and the Partnership holds the stock for the benefit of its investors.

Key Figures

Beneficially owned securities: 953,739 shares Common Shares held: 703,739 shares Warrants to acquire Common Shares: 250,000 shares +4 more

7 metrics

Beneficially owned securities 953,739 shares Total securities beneficially owned by each reporting person

Common Shares held 703,739 shares Component of the Stonepine group’s beneficial ownership

Warrants to acquire Common Shares 250,000 shares Warrants held, subject to a 9.99% beneficial ownership limitation

Percent of class owned 6.9% Beneficial ownership percentage for each reporting person

Shares outstanding after offering 13,503,723 shares Common Shares outstanding immediately after the offering, per August 20, 2026 prospectus

Sole voting power 0 shares Each reporting person’s sole voting power over Edesa common shares

Shared voting power 953,739 shares Each reporting person’s shared voting power over Edesa common shares

Key Terms

Schedule 13G, beneficial ownership limitation, beneficially owned, pecuniary interest, +1 more

5 terms

Schedule 13G regulatory

"EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial ownership limitation financial

"warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

beneficially owned financial

"The securities beneficially owned by the reporting persons consist of (1) 703,739 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

pecuniary interest financial

"Each reporting person also disclaims beneficial ownership of shares of Common Shares except to the extent of that person's pecuniary interest"

shared dispositive power financial

"Shared Dispositive Power 953,739.00"

FAQ

What percentage of Edesa Biotech, Inc. (EDSA) does Stonepine report owning?

Stonepine Capital Management, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico report beneficial ownership of 6.9% of Edesa Biotech’s common shares, based on 13,503,723 shares outstanding immediately after an offering described in an August 20, 2026 prospectus.

How many Edesa Biotech (EDSA) shares and warrants does Stonepine beneficially own?

The reporting persons beneficially own 953,739 Edesa Biotech securities, consisting of 703,739 common shares and warrants to acquire an additional 250,000 common shares, all subject to a stated 9.99% beneficial ownership limitation on the warrants.

How is voting and dispositive power over EDSA shares allocated among the Stonepine filers?

Stonepine Capital Management, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico each report 0 shares with sole voting or dispositive power and 953,739 shares with shared voting and dispositive power over Edesa Biotech common shares.

What share count did the Stonepine group use to calculate its 6.9% stake in EDSA?

The 6.9% ownership figure is calculated using 13,503,723 Edesa Biotech common shares outstanding immediately after an offering, as reported in a prospectus filed by Edesa Biotech on August 20, 2026.

What limitation applies to Stonepine’s EDSA warrants?

The warrants held by the reporting persons to acquire 250,000 Edesa Biotech common shares are subject to a 9.99% beneficial ownership limitation, which restricts exercises that would cause aggregate beneficial ownership to exceed that threshold.

Who ultimately benefits from the EDSA shares held by Stonepine Capital, L.P.?

Stonepine Capital, L.P. holds Edesa Biotech common stock for the benefit of its investors and has the right to receive, or direct the receipt of, dividends and proceeds from the sale of the common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:41 PM Accepted by SEC EDGAR 08/26/2026 - 04:41 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Edesa Biotech, Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

27966L306

(CUSIP Number)

08/20/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 27966L306

1

Names of Reporting Persons

Stonepine Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 953,739.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 953,739.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

953,739.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 703,739 shares of Common Shares and (2) warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 13,503,723 shares of Common Shares outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on August 20, 2026.

SCHEDULE 13G

CUSIP Number(s): 27966L306

1

Names of Reporting Persons

Stonepine Capital, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 953,739.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 953,739.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

953,739.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 703,739 shares of Common Shares and (2) warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 13,503,723 shares of Common Shares outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on August 20, 2026.

SCHEDULE 13G

CUSIP Number(s): 27966L306

1

Names of Reporting Persons

Stonepine GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 953,739.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 953,739.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

953,739.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 703,739 shares of Common Shares and (2) warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 13,503,723 shares of Common Shares outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on August 20, 2026.

SCHEDULE 13G

CUSIP Number(s): 27966L306

1

Names of Reporting Persons

Jon M. Plexico

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 953,739.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 953,739.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

953,739.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 703,739 shares of Common Shares and (2) warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 13,503,723 shares of Common Shares outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on August 20, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Edesa Biotech, Inc.
(b)	Address of issuer's principal executive offices: 100 Spy Court, Markham, ON, Canada L3R 5H6
Item 2.
(a)	Name of person filing: Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, LP, a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of shares of Common Shares except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any shares of Common Shares covered by this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 2900 NW Clearwater Drive, Suite 100-11, Bend OR 97703
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Common Shares
(e)	CUSIP Number(s): 27966L306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Stonepine: 953,739 Partnership: 953,739 General Partner: 953,739 Jon M. Plexico: 953,739
(b)	Percent of class: Stonepine: 6.9% Partnership: 6.9% General Partner: 6.9% Jon M. Plexico: 6.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0
	(ii) Shared power to vote or to direct the vote: Stonepine: 953,739 Partnership: 953,739 General Partner: 953,739 Jon M. Plexico: 953,739
	(iii) Sole power to dispose or to direct the disposition of: Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0
	(iv) Shared power to dispose or to direct the disposition of: Stonepine: 953,739 Partnership: 953,739 General Partner: 953,739 Jon M. Plexico: 953,739
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Stonepine Capital Management, LLC

Signature:	/s/ Jon M. Plexico
Name/Title:	Managing Member
Date:	08/26/2026

Stonepine Capital, L.P.

Signature:	/s/ Jon M. Plexico
Name/Title:	Managing Member of the General Partner, Stonepine GP, LLC
Date:	08/26/2026

Stonepine GP, LLC

Signature:	/s/ Jon M. Plexico
Name/Title:	Managing Member
Date:	08/26/2026

Jon M. Plexico

Signature:	/s/ Jon M. Plexico
Name/Title:	Reporting Person
Date:	08/26/2026

Exhibit Information

EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G.